Market Overview

Celldex Shares Spike Higher, Remain Volatile Following Co. Release Showing Interim Update from Phase 2 ReACT Study of Rindopepimut Demonstrated Statistically Significant Survival Benefit

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Posted-In: News FDA Movers

 

Related Articles (CLDX)